| Theme |
Novel therapeutic strategy for ulcerative colitis |
| Title |
Infliximab therapy for ulcerative colitis |
| Author |
Hiroaki Ito |
Kinshukai Infusion Clinic |
| [ Summary ] |
Infliximab is a monoclonal antibody used to inhibit TNF-alpha production. The safety and efficacy of infliximab for the treatment of ulcerative colitis has been shown in two large randomized placebo-controlled trials known as ACT1 and ACT2. Infliximab has been shown to induce endoscopic remission, which leads to a reduced need for surgery. However, only a small number of predictors of response to infliximab therapy are available. Infliximab has not yet been fully accepted as a conventional therapy for the aforementioned conditions. |